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aost acute coronary syndromes (ACS) are caused by throm-
oses occurring over ruptured vulnerable plaques (1). While
he role of classical risk factors in atherogenesis is consolidated
2,3), their direct effect in acute plaque rupture and thrombosis
s unproven: ACS can occur in individuals without risk factors
4), and most individuals with coronary atherosclerosis do not
evelop ACS (5). The peripheral biochemical phenotype of
atients with ACS is progressively diverging from that of
atients with chronic ischemic syndromes, and although the
iology of ACS is highly subordinated to local factors, risk is
etter predicted by new sensitive, specific biomarkers of plaque
nstability (6) than by classical risk factors. These include acute
hase reactants, cytokines, markers of platelet activation and
xidative stress, angiogenic growth factors, increased cell ad-
esiveness, and matrix metalloproteases (7), and they are
arkers of ACS and players in plaque instability (e.g., high-
ensitivity C-reactive protein [hs-CRP] actively participates in
ndothelial dysfunction, atherosclerotic plaque formation,
laque maturation, plaque destabilization, and eventual rup-
ure) (8). High values of CRP are associated with rapid disease
rogression (9) and higher number of vulnerable plaques (10).
See page 2081
In this issue of the Journal, Tziakas et al. (11) propose the
otal cholesterol erythrocyte membrane (CEM) as a marker
f clinical instability: CEM was found to be significantly
igher in patients with ACS than in patients with chronic
table angina (CSA) (11). If confirmed in larger case and
ontrol series, CEM could become an easy, low-cost indi-
ator of instability in clinical settings. Data on the relation
etween CEM and circulating levels of cholesterol are
onflicting: in Tziakas et al. (11) patient population, CEM
evels were unrelated to circulating levels of cholesterol, and
imilar results have been reported in patients with combined
yperlipidemia and in normal controls (12). Prior human
13) and experimental studies (14) suggested that CEM is
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.t
From the Centre for Inherited Cardiovascular Diseases, IRCCS Policlinico San
atteo, Pavia, Italy.n equilibrium with the plasma cholesterol concentration.
he relation between CEM and circulating levels of cho-
esterol needs to be further investigated using a unique
tandardized method in order to establish population-based
ormal reference ranges.
The hypothesis that CEM plays a role in clinical insta-
ility is biologically plausible: the rupture of a vulnerable
laque to cause ACS depends at least partly on the size of
he pultaceous core (15). Free cholesterol constitutes about
ne-fourth of total plaque lipids within the core, and it is
resent in significantly higher amounts in vulnerable and
uptured plaques than in stable lesions (16). Sources of free
holesterol in the plaques are apoptotic/necrotic foam cells
nd lipoproteins whose cholesterol is, however, mostly
sterified (17). The main candidates for accumulation of
ree cholesterol in atherosclerotic plaques are erythrocytes
hose free cholesterol content exceeds that of all other cells
18). Erythrocyte membranes consist of 40% lipids (triglyc-
rides, phospholipids, and cholesterol), 52% proteins, and
% carbohydrates. Cholesterol is wedged between phospho-
ipid tails in the lipid bilayer. It stabilizes the membrane and
mproves impermeability to small, water-soluble molecules
18,19).
Proteins provide membranes with their specific, cell-
elated functions. Among the 50 proteins identified to date
n the erythrocyte membrane, glycophorin A (GPA) is an
ntegral protein expressed only in erythrocyte membranes.
lycophorin A influences elasticity, plays an important role
n preventing red cell aggregation in the circulation, and
ontributes to the glycocalyx (20). In 2002, we showed that
nti–GPA-immunostained material is a major component
f the pultaceous core of the large atherosclerotic plaques
hat form in the pulmonary arteries of patients diagnosed
ith chronic thromboembolic pulmonary hypertension, a
uman spontaneous model of atherosclerosis in individuals
ithout risk factors (21). In 2003, Kolodgie et al. (22)
eported that erythrocyte membranes are present in the
ecrotic core of advanced coronary atheromas and that
egree of anti-GPA immunostaining and iron accumulation
orrelated with the size of the necrotic core. Plaque growth
nd pultaceous core formation and progression may be due
o red cells entering the plaque, through constant leakage of
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May 29, 2007:2090–2 Editorial Commentrythrocytes from neovascularization; through larger in-
raplaque hemorrhages from ruptured microvessels; or
hrough thrombi from healed ruptures within the plaques
23). The presence of GPA in the cores of the atheroscle-
otic plaques is the signature of the erythrocyte-derived
rigin of part of the plaque core. The challenging question
s the link between the higher levels of CEM in patients
ith ACS versus patients with CSA found by Tziakas et al.
11) and the local plaque events that cause ACS. These
uthors did not study plaques but patients, and the study
oes not demonstrate a correlation between the core com-
osition of the culprit plaques and CEM. They did show,
owever, that CEM levels were associated with angio-
raphically complex coronary lesions (11) that predict
apid disease progression and adverse prognosis in pa-
ients with established coronary artery disease (24). They
ypothesize a link between CEM levels and clinical
nstability, which may reflect atheromatous plaque insta-
ility. Similar correlations have been shown for other
CS markers such as CRP (25).
Does the Tziakas et al. (11) hypothesis link plaque core
ize and composition with CEM? Plaque core formation
nd growth likely progress slowly. Accordingly, it is difficult
o consider CEM as a potential active player in acute plaque
vents causing ACS. Local plaque factors influencing rapid
ize changes could include both inflammatory and hemor-
hagic processes. The amount of red cells incorporated into
he plaque, their total lipid composition and CEM content,
s well as failure by the core microenvironment and mac-
ophage activity to clear necrotic red cells could influence
laque core size and composition. Nonlocal factors could
lso contribute. Membrane lipids are major active players in
uidity, aggregability, adherence, and deformability of
rythrocytes: fluidity decreases as the cholesterol content
ncreases (12). Erythrocyte aggregability increases in myo-
ardial infarction, angina, inflammation, diabetes, hyperten-
ion, and stroke; adherence to endothelial cells increases in
nflammation diabetes and stroke; deformability decreases
n infarction, angina, inflammation, diabetes, hypertension,
nd stroke (26). Cholesterol erythrocyte membrane is a
ynamic component of the erythrocyte membrane lipids
hat is subject to modifications associated with a variety of
hysiological, pathological, and pharmacologic conditions:
t has been reported to increase with age (27), chronic
lcohol assumption (28), obesity in women (29), pregnancy-
nduced hypertension (30), and after cyclosporine A admin-
stration (31). Cholesterol erythrocyte membrane decreases
fter exercise (32), in nephrotic syndrome (33), rheumatoid
rthritis (34), and cerebral hemorrhage (35).
Although widely investigated either as total cholesterol
ontent or phospholipid/cholesterol ratio, CEM did not
nd relevant clinical applications. A simple, standardized,
eproducible analytical procedure would facilitate further
tudies aimed at validating CEM as a marker of ACS and
nvestigating the effects of drugs on membrane cell compo-
ents. The low CEM levels in patients taking statins, shown
2y Tziakas et al. (11), suggest that statins could influence
ed cell membrane homeostasis and composition: the pleo-
orphic effects of statin at the cell membrane level and that
f other drugs on CEM represent promising new directions
or research.
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